Biocon Biologics and Yoshindo Expand Access to Ustekinumab Biosimilar in Japan

NOTIFICATION TO STOCK EXCHANGE COMPANY STATEMENT Bengaluru, Karnataka, India, May 21, 2025 Biocon Biologics Ltd (BBL) , a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that its commercial partner in Japan, Yoshindo Inc., has launched Ustekinumab BS Subcutaneous Injection [YD] , a biosimilar to the reference product Stelara® (ustekinumab). The biosimilar ustekinumab, developed and manufactured by Biocon Biologics, is commercialized and marketed in Japan by Yoshindo Inc. Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA) . In April 2024, the Company entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Ustekinumab in Japan upon regulatory approval. Biocon Biologics’ biosimilar Ustekinumab BS Subcutaneous Injection [YD] was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in December 2024 . Biocon Biologics has already launched Ustekinumab in the United States and Europe in February 2025 to help patients manage their chronic conditions. – Company Spokesperson Download Company Statement

The release as fetched from its publisher. bioconbiologics.com ↗